U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07829185) titled 'Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer' on Sept. 14.
Brief Summary: The purpose of this research is to observe the effects of using a new combination of drugs to inhibit tumor growth.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Pancreatic Ductal Adenocarcinoma (PDAC)
Intervention:
DRUG: modified FOLFIRINOX
In Arm A (up to 15 patients) will be treated with modified FOLFIRINOX every two weeks, delivered as follows:
* Oxaliplatin 85mg/m2 IV over 2 hours on Day 1, followed by,
* Irinotecan 150mg/m2 IV over 90 minutes on Day 1, followed by
* Leucovorin 400mg/m2 I...